What are the indications, dosing, and contraindications for using propranolol in the treatment of supraventricular tachycardia (SVT)?

Propranolol for SVT: Indications, Dosing, and Contraindications

Propranolol is a reasonable second-line agent for acute SVT termination in hemodynamically stable patients, but intravenous beta blockers are less effective than calcium channel blockers (diltiazem/verapamil) or adenosine, and oral propranolol combined with diltiazem may be used when IV access is unavailable. 1

Indications

Acute Treatment

• Intravenous beta blockers (including propranolol) carry a Class IIa recommendation for acute termination of hemodynamically stable AVNRT and other SVTs, but evidence shows they are inferior to diltiazem for conversion 1
• FDA-approved indication: IV propranolol is indicated for short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome, to decrease ventricular rate 2
• Oral propranolol (Class IIb recommendation) may be reasonable when combined with diltiazem for acute SVT termination, particularly when IV access is unavailable 1, 3

Ongoing Management

The 2015 ACC/AHA/HRS guidelines notably do not include beta blockers as a Class I recommendation for ongoing SVT management—calcium channel blockers (verapamil/diltiazem) hold this distinction 1. The 2019 ESC guidelines actually downgraded beta blockers for chronic AVNRT management 4.

Special Populations

• Pediatric SVT: High-dose oral propranolol (7-14 mg/kg/day, average 9 mg/kg/day) has shown efficacy in infants and children with SVT refractory to digoxin, with 67-88% success rates 5, 6
• Pregnancy: Propranolol is no longer recommended during pregnancy per 2019 ESC guidelines 4

Dosing

Intravenous Administration

• Critical safety note: IV propranolol should be given in low dosage and very slowly due to risk of myocardial depression 2
• Use with constant ECG and central venous pressure monitoring, especially during anesthesia 2
• Reserved for life-threatening arrhythmias or those occurring under anesthesia 2

Oral Administration

• Acute termination: 160 mg propranolol combined with 120 mg diltiazem as single dose (converted 14/15 patients in average 27 minutes) 3
• Pediatric dosing: 7-14 mg/kg/day divided doses (average 9 mg/kg/day) 6
• Infant dosing: Mean 3.6 ± 1.0 mg/kg/day 5

Contraindications (Absolute)

Per FDA labeling, propranolol is absolutely contraindicated in 2:

1. Cardiogenic shock
2. Sinus bradycardia and greater than first-degree AV block
3. Bronchial asthma
4. Known hypersensitivity to propranolol

Critical Safety Considerations

When to Avoid

• Systolic heart failure: The failing heart requires sympathetic drive for myocardial tone maintenance 2
• During anesthesia: All general inhalation anesthetics produce myocardial depression; extreme caution required 2
• First trimester pregnancy: All antiarrhythmic drugs should be avoided 7

Adverse Events

• Severe bradycardia may occur, especially in digitalis toxicity 2
• Two patients in one study developed transient second-degree AV block and junctional rhythm with oral propranolol/diltiazem combination 3
• Only 1/287 infants experienced clinically significant adverse events requiring discontinuation in a large pediatric series 5

Clinical Algorithm

For acute hemodynamically stable SVT:

1. First-line: Vagal maneuvers, then adenosine (95% effective) 1
2. Second-line: IV diltiazem or verapamil (more effective than beta blockers) 1
3. Third-line: IV beta blockers (including propranolol) if calcium channel blockers contraindicated or failed 1
4. Consider oral propranolol + diltiazem if no IV access 1

For hemodynamically unstable SVT:

• Synchronized cardioversion after failed vagal maneuvers/adenosine 1

Predictors of propranolol failure:

• Congenital heart disease (OR 0.42) 5
• Wolff-Parkinson-White syndrome (OR 0.42) 5

Key Pitfalls

• Do not use in wide-QRS tachycardia of unknown origin (risk of ventricular fibrillation if pre-excited AF) 1
• Avoid in suspected systolic heart failure (unlike calcium channel blockers which have similar restriction) 1
• Beta blockers are less predictable for SVT termination than calcium channel blockers—diltiazem was superior to esmolol in head-to-head comparison 1
• The "pill-in-the-pocket" approach with propranolol is no longer recommended per 2019 ESC guidelines 4